Postoperative care drives majority of expenses after Lucia KPro surgery
Key Takeaways
- Postoperative care accounted for the majority of total costs, largely due to complication management.
- Glaucoma, retroprosthetic membranes, and epithelial defects were the most common complications.
- Patients experienced significant visual improvement with high rates of anatomic retention.
Implantation of the Lucia Keratoprosthesis (KPro) in a resource-limited tertiary center was associated with substantial postoperative costs, primarily driven by complication management, while still demonstrating meaningful visual improvement and high rates of anatomic retention, according to a study.
Researchers conducted a retrospective chart review of 24 patients (24 eyes) who underwent Lucia KPro implantation.
The mean follow-up period was 34 months.
- Average total cost per patient: $6,949.55 ± $1,344.54
- Initial surgery cost: $2,582.31 ± $980.13
- Postoperative care: Accounted for 62.84% of total costs
- Expenses were largely related to medical and surgical management of complications
Most common complications:
- Glaucoma (37.5%)
- Retroprosthetic membranes (33.3%)
- Epithelial defects (16.7%)
Visual outcomes improved over the study period. Mean BCVA improved from 2.40 ± 0.28 LogMAR preoperatively to 1.32 ± 1.03 LogMAR at final follow-up, a mean gain of 1.08 LogMAR (P < 0.001). Anatomic retention was reported in 95.83% of cases, and 62.50% of patients achieved functional success, defined as BCVA of 20/200 or better.
The authors concluded that the Lucia KPro may serve as a cost-conscious option for managing corneal blindness in resource-limited settings, though postoperative care remains a significant contributor to overall costs. They noted that efforts to reduce complications, incorporate telemedicine follow-up, and implement national subsidy programs may help improve accessibility and financial feasibility.
Reference
Ortiz-Morales G, Muleiro-Alvarez M, Soberanes-Velarde J, et al. Cost analysis of the Lucia keratoprosthesis in a resource-limited tertiary care center. Int Ophthalmol. 2026;46(1):121. doi: 10.1007/s10792-026-03989-w. PMID: 41706250.
